Comparative Pharmacology
Head-to-head clinical analysis: DAYSEE versus ENOVID E.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DAYSEE versus ENOVID E.
DAYSEE vs ENOVID-E
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DAYSEE (estradiol/norethindrone acetate) is a combination hormonal contraceptive that suppresses gonadotropins (FSH and LH) via negative feedback of estrogen and progestin, thereby inhibiting ovulation. Norethindrone also increases cervical mucus viscosity and induces endometrial atrophy.
Combination estrogen-progestin contraceptive. Suppresses gonadotropin release, inhibits ovulation, increases cervical mucus viscosity, and alters endometrial morphology.
One active tablet (norgestimate 0.18 mg/ethinyl estradiol 0.025 mg) orally once daily for 21 days, followed by 7 days of placebo. Each cycle: 7 days placebo, then 21 days active.
5 mg orally once daily for 20 days starting on day 5 of menstrual cycle
None Documented
None Documented
Terminal elimination half-life is approximately 24 hours (range 18-36 hours), supporting once-daily dosing for steady state within 5 days.
Norethynodrel: 5-10 hours; mestranol: 2-5 hours (metabolized to ethinyl estradiol, half-life 10-20 hours). Steady-state reached in 5-7 days.
Renal 70% (metabolites), biliary/fecal 30% (parent drug and metabolites). No active drug excreted unchanged.
Renal (50-60% as metabolites, <1% unchanged); fecal (40-50%)
Category C
Category C
Oral Contraceptive
Oral Contraceptive